Browsing Tag
Glenmark Pharmaceuticals
43 posts
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
Glenmark Pharmaceuticals surges 10% after AbbVie licensing deal boosts ISB 2001 global reach
Glenmark Pharmaceuticals stock jumps 10% after announcing ISB 2001 licensing deal with AbbVie; find out what this could mean for its oncology ambitions.
RYALTRIS: Glenmark’s quiet blockbuster? A 45-market launch strategy explained
RYALTRIS is Glenmark’s global allergy brand launched in 45+ countries. Explore how it’s reshaping the firm’s branded strategy and global revenue mix.
Pharma stock watch: Are Indian midcaps like Glenmark better positioned than the giants?
Are Indian midcap pharma stocks like Glenmark set to outperform giants like Sun and Cipla? Explore 2025 trends, biotech bets, and market sentiment shifts.
Glenmark Pharmaceuticals eyes biotech leap as ISB 2001 enters global spotlight
Glenmark Pharmaceuticals’ ISB 2001 gets FDA Fast Track for multiple myeloma. Explore how this could redefine its biotech future and rival global oncology innovators.
Glenmark Pharmaceuticals posts 12.8% revenue rise in FY25, beats market estimates
Glenmark Pharma posts ₹13,894 Cr profit in FY25. Explore its global growth, R&D breakthroughs, and why ISB 2001 may define its biotech future.
Glenmark Pharmaceuticals expands U.S. OTC market presence with Olopatadine Eye Drops
Glenmark secures FDA approval for its OTC Olopatadine Hydrochloride eye drops, expanding its U.S. presence in the $50.7M allergy relief market.
Glenmark Pharmaceuticals expands cardiometabolic portfolio with new Empagliflozin drug launch
Glenmark Pharmaceuticals Ltd. has introduced Empagliflozin, a widely recognized SGLT2 inhibitor, in India under the brand name Glempa.…
Glenmark Pharmaceuticals posts strong Q3 FY2025 earnings as global expansion gains momentum
Glenmark Pharmaceuticals Limited has reported a strong financial performance for the third quarter of fiscal year 2025, driven…
Ichnos Glenmark presents data from Phase 1 study of ISB 2001 in multiple myeloma
In a presentation at the 66th American Society of Hematology Annual Meeting, Ichnos Glenmark Innovation (IGI) unveiled promising…